tetano
Editor, Senior Moderator
Expert Opin Pharmacother
. 2023 Sep 21.
doi: 10.1080/14656566.2023.2262387. Online ahead of print. Paxlovid as a potential treatment for long COVID
Matthew W McCarthy[SUP] 1 [/SUP]
Affiliations
Introduction: On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health opened enrollment for RECOVER-Vital, a randomized study to evaluate new treatment options for long Coronavirus (long COVID).
Areas covered: The RECOVER Initiative is a $1.15 billion research platform intended to describe, categorize, treat, and prevent long-term symptoms following infection by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2), the virus that causes Coronavirus (COVID-19). More than 200 symptoms have been associated with long COVID, potentially affecting nearly all body systems, and current estimates suggest that between 7 million and 23 million Americans have developed long COVID. However, there are no approved treatments for this condition.
Expert opinion: The first prospective, randomized study of the RECOVER research initiative, RECOVER-Vital, will evaluate the SARS-CoV-2 antiviral nirmatrelvir/ritonavir (Paxlovid) as a potential treatment for long COVID. This manuscript explores what is known about Paxlovid to treat and prevent long COVID and examines the rationale for addressing this condition with an antiviral agent.
Keywords: Long COVID; SARS-CoV-2; nirmatrelvir; paxlovid; ritonavir.
. 2023 Sep 21.
doi: 10.1080/14656566.2023.2262387. Online ahead of print. Paxlovid as a potential treatment for long COVID
Matthew W McCarthy[SUP] 1 [/SUP]
Affiliations
- PMID: 37731377
- DOI: 10.1080/14656566.2023.2262387
Introduction: On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health opened enrollment for RECOVER-Vital, a randomized study to evaluate new treatment options for long Coronavirus (long COVID).
Areas covered: The RECOVER Initiative is a $1.15 billion research platform intended to describe, categorize, treat, and prevent long-term symptoms following infection by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2), the virus that causes Coronavirus (COVID-19). More than 200 symptoms have been associated with long COVID, potentially affecting nearly all body systems, and current estimates suggest that between 7 million and 23 million Americans have developed long COVID. However, there are no approved treatments for this condition.
Expert opinion: The first prospective, randomized study of the RECOVER research initiative, RECOVER-Vital, will evaluate the SARS-CoV-2 antiviral nirmatrelvir/ritonavir (Paxlovid) as a potential treatment for long COVID. This manuscript explores what is known about Paxlovid to treat and prevent long COVID and examines the rationale for addressing this condition with an antiviral agent.
Keywords: Long COVID; SARS-CoV-2; nirmatrelvir; paxlovid; ritonavir.